secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001558370-23-009383
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma Q3 revenue $22.7M (-6% YoY); net loss narrows to $7.2M
---------------------------------------------------------------------

- Total net revenue $22.7M, down 6% from $24.2M; net loss ($7.2M) vs ($53.3M) last year.
- Record total prescriptions 153,452 (+32% YoY); ADHD prescriptions up 27%.
- Rx segment revenue $13.8M; ADHD revenue down 21% to $8.3M due to $1.2M channel inventory adjustment.
- Pediatric products revenue up 81% to $5.3M; Consumer Health down 14% to $8.9M.
- Gross margin improved to 56% from 52%; cash $19.2M; FDA approval for Adzenys manufacturing transfer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023009383/0001558370-23-009383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023009383/aytu-20230511x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-009383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer